Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IOngoingJul 24, 2024Potassium Chloride Extended-Release CapsulesFailed Dissolution SpecificationsGlenmark Pharmaceuticals Inc., USA · D-0604-2024Class IICompletedJul 24, 2024Cardura XLFailed Impurities/Degradation SpecificationsViatris Inc · D-0603-2024Class IICompletedJul 24, 2024Cardura XLFailed Impurities/Degradation SpecificationsViatris Inc · D-0602-2024Class IIOngoingJul 24, 2024Fludrocortisone Acetate TabletsFailed Impurities/Degradation Specifications: Product is being recalled due to API related substances and unknown impurities that are above the specification limits.Teva Pharmaceuticals USA, Inc · D-0601-2024Class IITerminatedJul 24, 2024Cyanocobalamin InjectionPresence of particulate matter: glassZydus Pharmaceuticals (USA) Inc · D-0600-2024Class IIOngoingJul 24, 2024Oatmeal Daily Moisturizing Body LotionMicrobial Contamination of Non-Sterile Products: confirmed presence of mold contaminationBrands International Corporation · D-0598-2024Class IITerminatedJul 24, 2024Nitrofurantoin CapsulesFailed Dissolution SpecificationsSun Pharmaceutical Industries Inc · D-0597-2024Class IIIOngoingJul 17, 2024Diflorasone Diacetate OintmentFailed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit.Rising Pharma Holding, Inc. · D-0599-2024Class IIICompletedJul 17, 2024Micafungin for injectionCross contamination with other productsZydus Pharmaceuticals (USA) Inc · D-0596-2024Class IIICompletedJul 17, 2024Micafungin for injectionCross contamination with other productsZydus Pharmaceuticals (USA) Inc · D-0595-2024Class IIOngoingJul 17, 2024Lidocaine HCL InjectionSubpotent Drug: reduced efficacy for epinephrineTailstorm Health Inc · D-0594-2024Class IIIOngoingJul 17, 2024Verapamil Hydrochloride InjectionCross contamination with other products.Zydus Pharmaceuticals (USA) Inc · D-0593-2024Class IIIOngoingJul 17, 2024Verapamil Hydrochloride InjectionCross contamination with other products.Zydus Pharmaceuticals (USA) Inc · D-0592-2024Class IITerminatedJul 17, 2024Blemfree All Day LotionCGMP Deviations: Manufactured without following Current Good Manufacturing Practises.Equibal Inc · D-0591-2024Class IIOngoingJul 17, 2024buPROPion Hydrochloride Extended-release Tablets USPFailed Dissolution Specifications; the product is dissolving faster than the specified limits.Amerisource Health Services LLC · D-0590-2024Class IIOngoingJul 17, 2024suntegrityCGMP DeviationsSynchronicity Spa Inc, Dba Sunte · D-0589-2024Class IOngoingJul 17, 2024suntegrityMicrobial Contamination of Non-Sterile Products: Presence of Aspergillus Sydowii (Mold)Synchronicity Spa Inc, Dba Sunte · D-0588-2024Class IIOngoingJul 17, 2024Dianeal Low CalciumLack of Assurance of Sterility: Potential presence of leaks originating from the Connector Assembly component.Baxter Healthcare Corporation · D-0587-2024Class IOngoingJul 10, 2024To the Moon CapsulesMarketed Without an Approved NDA/ANDA: Products contain undeclared sildenafil.Integrity Products · D-0586-2024Class IOngoingJul 10, 2024RAM IT, Horny Goat WeedMarketed Without an Approved NDA/ANDA: Products contain undeclared sildenafil.Integrity Products · D-0585-2024Class IITerminatedJul 10, 2024Venlafaxine HydrochlorideFailed dissolution specifications: out of specification result obtained during routine stability testing for high dissolution.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0584-2024Class IITerminatedJul 10, 2024Allopurinol TabletsPresence of foreign substance.Dr. Reddy's Laboratories, Inc. · D-0583-2024Class IIOngoingJul 10, 2024Decitabine for Injection 50mg per vialCGMP Deviations: Out of Specification for Total Aerobic Microbial Count (TAMC) test for unfiltered bulk for decitabine for injection.Sun Pharmaceutical Industries Inc · D-0582-2024Class IIIOngoingJul 10, 2024Eszopiclone TabletsFailed Impurities/Degradation Specifications: Related SubstancesDr. Reddy's Laboratories, Inc. · D-0581-2024Class IIITerminatedJul 10, 2024Dodex InjectableSubpotent drug: out of specification resultsAccord Healthcare, Inc. · D-0580-2024Class IITerminatedJul 10, 2024Methylphenidate HydrochlorideFailed dissolution specifications: this product is being recalled due to this batch not meeting dissolution specifications.Trigen Laboratories · D-0579-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0578-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0577-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0576-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0575-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0574-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0573-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0572-2024Class IIOngoingJul 10, 2024Little Moon EssentialsCGMP deviationsLittle Moon Essentials LLC · D-0571-2024Class IICompletedJul 10, 2024BudesonideCGMP Deviations and Presence of Particulate Matter: GlassMedisca Inc. · D-0570-2024Class IIIOngoingJul 3, 2024SinuFrin DecongestantSub-potent DrugNeilmed Pharmaceuticals Inc · D-0569-2024Class IITerminatedJul 3, 2024Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.Golden State Medical Supply Inc. · D-0568-2024Class IIOngoingJul 3, 2024ZilrettaFailed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿CPacira Pharmaceuticals Inc · D-0567-2024Class IIOngoingJul 3, 2024Extra Strength Acetaminophen 500 MG TabletsDiscoloration: Brownish tabletsContract Pharmacal Corporation · D-0566-2024Class IIOngoingJul 3, 2024Labetalol Hydrochloride InjectionLack of Assurance of Sterility-The potential for incomplete crimp seals.Pfizer Inc. · D-0565-2024